Exelixis (EXEL) Operating Leases (2018 - 2026)
Exelixis (EXEL) recorded quarterly Operating Leases of $169.5 million in Q2 2026, down 2.02% quarter-over-quarter from $173.0 million in Q1 2026, and down 9.4% on a YoY basis from $187.1 million in Q2 2025.
Exelixis (EXEL) Operating Leases (2018 - 2026) Analysis & Trends
Exelixis' Operating Leases history runs 8 years deep, the most recent figure standing at $169.5 million for Q2 2026.
- In Q2 2026, Operating Leases fell 9.4% year-over-year to $169.5 million; the TTM figure through Apr 2026 stood at $169.5 million (down 9.4% YoY), while the FY2026 annual figure was $173.0 million, down 19.83% from the prior year.
- Operating Leases was $169.5 million for Q2 2026 at Exelixis, down from $173.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $215.8 million in Q1 2025 to a low of $50.6 million in Q2 2022.
- Historically, Operating Leases has averaged $178.7 million across 5 years, with a median of $187.1 million in 2025.
- The sharpest annual moves came in 2022 and 2026: Operating Leases surged 305.35% in 2022, then fell 19.83% in 2026.
- A 5-year view of Operating Leases shows it stood at $207.8 million in 2022, then retreated by 8.61% to $189.9 million in 2023, then rose by 2.37% to $194.4 million in 2024, then decreased by 9.25% to $176.5 million in 2025, then decreased by 3.92% to $169.5 million in 2026.
- The last three Operating Leases figures came in at $169.5 million (Q2 2026), $173.0 million (Q1 2026), and $176.5 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 169.54 Mn |
| Jan 2, 2026 | 173.04 Mn |
| Oct 3, 2025 | 176.46 Mn |
| Jul 4, 2025 | 179.84 Mn |
| Apr 4, 2025 | 187.13 Mn |
| Jan 3, 2025 | 215.83 Mn |
| Sep 27, 2024 | 194.45 Mn |
| Jun 28, 2024 | 198.02 Mn |
| Mar 29, 2024 | 201.47 Mn |
| Dec 29, 2023 | 189.94 Mn |
| Sep 29, 2023 | 190.86 Mn |
| Jun 30, 2023 | 194.69 Mn |
| Mar 31, 2023 | 186.95 Mn |
| Dec 30, 2022 | 207.83 Mn |
| Sep 30, 2022 | 159.84 Mn |
| Jul 1, 2022 | 161.02 Mn |
| Apr 1, 2022 | 50.64 Mn |
| Dec 31, 2021 | 51.27 Mn |
| Oct 1, 2021 | 52.25 Mn |
| Jul 2, 2021 | 53.22 Mn |